Maya Sabatello, Suzanne Bakken, Wendy K Chung, Elizabeth Cohn, Katherine D Crew, Krzysztof Kiryluk, Rita Kukafka, Chunhua Weng, Paul S Appelbaum
Return of polygenic risk scores in research: Stakeholders' views on the eMERGE-IV study
HGG advances
management gastrointestinal malignancy evolved tumor response assessment expanded sizebased assessments include tumor enhancement addition functional data derived pet diffusionweighted imaging accurate interpretation tumor response therefore requires knowledge imaging modalities used gastrointestinal malignancy anticancer therapies tumor biology targeted therapies immunotherapy pose additional considerations due unique imaging response patterns drug toxicity consequence immunotherapy response criteria developed gastrointestinal malignancies require assessment tumorspecific criteria assessing response often guide clinical management watchful waiting rectal cancer suitability surgery pancreatic cancer moreover anatomic measurements underestimate therapeutic response applied moleculartargeted therapies locoregional therapies hypervascular malignancies hepatocellular carcinoma cases responding tumors may exhibit morphologic changes including cystic degeneration necrosis hemorrhage often without significant reduction size awareness pitfalls interpreting gastrointestinal tumor response required correctly interpret response assessment imaging guide appropriate oncologic management datadriven image analyses radiomics investigated variety gastrointestinal tumors identifying likely respond therapy recur aim delivering precision medicine multimediaenhanced radiology reports facilitate communication gastrointestinal tumor response automatically embedding response categories key data representative images rsna 2024 test knowledge questions article available supplemental material